Ronapreve Flashcards
Indications for Ronapreve
Evidence comes from the three-phase REGEN-COV trial in which patients with one or more risk factors for disease progression received either 1200 mg, 2400 mg or 8000 mg casirivimab plus imdevimab. Based on inclusion criteria of the trial, risk factors for disease progression include:
Age ≥ 50 years
Obesity (≥ 30 kg/m2)
Cardiovascular disease (including hypertension)
Chronic lung disease (including asthma)
Type 1 or 2 diabetes mellitus
Chronic kidney disease, including those that are on dialysis
Chronic liver disease
Immunocompromised patients (including individuals with rheumatoid arthritis, HIV/AIDS and systemic lupus erythematosus)
As there is insufficient data supporting one dose over another, the Taskforce recommends that the most frequently used dose across studies (1200 mg) should be administered within 7 days of onset of symptoms.
The efficacy of casirivimab plus imdevimab in vaccinated or immunocompromised patients with mild or asymptomatic COVID-19 is not known.
As of 29 October 2021, the Taskforce has made conditional recommendations supporting the use of both sotrovimab and casirivimab plus imdevimab in adult outpatients with mild COVID-19. As there is no evidence directly comparing sotrovimab to casirivimab plus imdevimab, it is unclear if one treatment is more effective than the other.
